Enhanced efficacy of the CDNF/MANF family by combined intranigral overexpression in the 6-OHDA rat model of Parkinson's disease.
about
The Solution Structure and Dynamics of Full-length Human Cerebral Dopamine Neurotrophic Factor and Its Neuroprotective Role against α-Synuclein Oligomers.Recombinant AAV8-mediated intrastriatal gene delivery of CDNF protects rats against methamphetamine neurotoxicityTherapeutic efficacy of AAV8-mediated intrastriatal delivery of human cerebral dopamine neurotrophic factor in 6-OHDA-induced parkinsonian rat models with different disease progression.Evidence for an Additive Neurorestorative Effect of Simultaneously Administered CDNF and GDNF in Hemiparkinsonian Rats: Implications for Different Mechanism of Action.Viral vector delivery of neurotrophic factors for Parkinson's disease therapy.Therapeutic potential of the endoplasmic reticulum located and secreted CDNF/MANF family of neurotrophic factors in Parkinson's disease.Protection of Cultured Dopamine Neurons from MPP(+) Requires a Combination of Neurotrophic Factors.Effect of microgravity on glial cell line-derived neurotrophic factor and cerebral dopamine neurotrophic factor gene expression in the mouse brain.Neurotrophic factor therapy for Parkinson's disease: past, present and future.Cerebral Dopamine Neurotrophic Factor: A Potential Therapeutic Agent for Parkinson's Disease.Cerebral dopamine neurotrophic factor protects H9c2 cardiomyocytes from apoptosis.Mesencephalic astrocyte-derived neurotrophic factor attenuates inflammatory responses in lipopolysaccharide-induced neural stem cells by regulating NF-κB and phosphorylation of p38-MAPKs pathways.Gene Therapy for Parkinson's Disease, An Update.Bioactivity-Guided Isolation of Neuritogenic Factor from the Seeds of the Gac Plant (Momordica cochinchinensis).Expression and Distribution of Mesencephalic Astrocyte-Derived Neurotrophic Factor in the Retina and Optic NerveEmerging Roles for Mesencephalic Astrocyte-Derived Neurotrophic Factor (MANF) in Pancreatic Beta Cells and Diabetes
P2860
Q30376382-F543CCB0-212D-409F-A976-8516B0C8D9F3Q33702977-7E5FEEBD-55E3-4839-B190-A4B4AF3EEF08Q33807060-BC490B84-31F1-487B-BFF2-C6C8457499CEQ37693952-F380B4DF-47BD-449C-AE62-1D41BF9392EEQ38495722-72A1CB11-14BA-41CA-9C3F-E4C7F4A28929Q38602888-91B83DEF-71F8-47C9-AFA5-7EBC616EFB24Q38776707-CCDAE30A-2A81-40F1-A8B1-A2F350F819B0Q38878732-1359A542-DA38-418E-88D1-012D5736C30BQ38881852-216863F3-476E-485D-B256-71B6FCD4176AQ39197908-4405C18D-80A4-4571-BEA9-D8444AA1E503Q51034617-35F2B3B8-EE7B-4DB0-A954-9F2B7849D031Q53122724-E5BF4CFC-A250-4E6A-90B6-36439B3D2085Q55418920-09C54033-2D35-4F25-910D-5664665EFC2EQ55465960-E42B933E-FC47-421A-8C45-991918905668Q58493717-7FB7E733-B149-40EC-92E5-A9C8CB153F89Q58554232-EC858F62-324F-48B4-941A-167906123039
P2860
Enhanced efficacy of the CDNF/MANF family by combined intranigral overexpression in the 6-OHDA rat model of Parkinson's disease.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年学术文章
@wuu
2014年学术文章
@zh-cn
2014年学术文章
@zh-hans
2014年学术文章
@zh-my
2014年学术文章
@zh-sg
2014年學術文章
@yue
2014年學術文章
@zh
2014年學術文章
@zh-hant
name
Enhanced efficacy of the CDNF/ ...... model of Parkinson's disease.
@en
type
label
Enhanced efficacy of the CDNF/ ...... model of Parkinson's disease.
@en
prefLabel
Enhanced efficacy of the CDNF/ ...... model of Parkinson's disease.
@en
P2860
P50
P356
P1433
P1476
Enhanced efficacy of the CDNF/ ...... model of Parkinson's disease.
@en
P2860
P304
P356
10.1038/MT.2014.206
P4011
e5a1d3604be57ead544f59b6b97a16fe1dbd3c7a
P407
P577
2014-11-05T00:00:00Z